KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Income from Continuing Operations (2016 - 2025)

CRISPR Therapeutics AG's Income from Continuing Operations history spans 11 years, with the latest figure at 129699000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 135.43% year-over-year to 129699000.0; the TTM value through Dec 2025 reached 580684000.0, down 1663.08%, while the annual FY2025 figure was 580684000.0, 1662.62% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 129699000.0 at CRISPR Therapeutics AG, down from 106441000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 759225000.0 in Q2 2021 and bottomed at 208557000.0 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 114877000.0 (2021), against an average of 39476750.0.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 1053.13% in 2021 before it crashed 135.43% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 139523000.0 in 2021, then grew by 19.11% to 112857000.0 in 2022, then surged by 339.24% to 270002000.0 in 2023, then skyrocketed by 35.6% to 366115000.0 in 2024, then plummeted by 135.43% to 129699000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Income from Continuing Operations are 129699000.0 (Q4 2025), 106441000.0 (Q3 2025), and 208557000.0 (Q2 2025).